Plasma-derived Medical Product Market, Global Outlook and Forecast 2023-2028

Report ID: 1135997 | Published Date: Jan 2025 | No. of Page: 108 | Base Year: 2024 | Rating: 4.4 | Webstory: Check our Web story

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation
This report contains market size and forecasts of Plasma-derived Medical Product in Global, including the following market information:
Global Plasma-derived Medical Product Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Plasma-derived Medical Product market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immune Globulin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Plasma-derived Medical Product include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL and RAAS, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Plasma-derived Medical Product companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Plasma-derived Medical Product Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Plasma-derived Medical Product Market Segment Percentages, by Type, 2021 (%)
Immune Globulin
Coagulation Factor
Albumin
Other
Global Plasma-derived Medical Product Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Plasma-derived Medical Product Market Segment Percentages, by Application, 2021 (%)
Hospital
Retail Pharmacy
Other
Global Plasma-derived Medical Product Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Plasma-derived Medical Product Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Plasma-derived Medical Product revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Plasma-derived Medical Product revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics

Frequently Asked Questions
Plasma-derived Medical Product Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Plasma-derived Medical Product Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Plasma-derived Medical Product Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports